Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).

Halfon P, Pérusat S, Bourlière M, Bronowicki JP, Trimoulet P, Benhamou Y, Leroy V, Marcellin P, Foucher J, Penaranda G, Chêne G, Couzigou P; ANRS HC16 GAMMATRI Study Group.

J Med Virol. 2010 Dec;82(12):2027-31. doi: 10.1002/jmv.21909.

PMID:
20981789
[PubMed - indexed for MEDLINE]
2.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
3.

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.

Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P.

Liver Int. 2010 Oct;30(9):1259-69. doi: 10.1111/j.1478-3231.2010.02283.x. Review.

PMID:
20633102
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

Asselah T, Marcellin P.

Liver Int. 2011 Jan;31 Suppl 1:68-77. doi: 10.1111/j.1478-3231.2010.02411.x. Review.

PMID:
21205141
[PubMed - indexed for MEDLINE]
5.

Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.

Forestier N, Zeuzem S.

Liver Int. 2012 Feb;32 Suppl 1:44-50. doi: 10.1111/j.1478-3231.2011.02720.x. Review.

PMID:
22212571
[PubMed - indexed for MEDLINE]
6.

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.

Health Technol Assess. 2007 Mar;11(11):1-205, iii. Review.

PMID:
17346498
[PubMed - indexed for MEDLINE]
Free Article
7.

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.

Pawlotsky JM.

Hepatology. 2011 May;53(5):1742-51. doi: 10.1002/hep.24262. Review.

PMID:
21374691
[PubMed - indexed for MEDLINE]
8.

[Present status of clinical trials on long-acting IFNs preparations (PEG-IFN alpha 2a, alpha 2b, IFN alpha-minipellet)].

Tanikawa K.

Nihon Rinsho. 2001 Jul;59(7):1369-73. Review. Japanese.

PMID:
11494553
[PubMed - indexed for MEDLINE]
9.

Mechanisms of non-response to antiviral treatment in chronic hepatitis C.

Chevaliez S, Asselah T.

Clin Res Hepatol Gastroenterol. 2011 Jun;35 Suppl 1:S31-41. doi: 10.1016/S2210-7401(11)70005-5. Review.

PMID:
21742299
[PubMed - indexed for MEDLINE]
10.

Hepatitis C pharmacogenetics: state of the art in 2010.

Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB; Pharmacogenetics and Hepatitis C Meeting Participants.

Hepatology. 2011 Jan;53(1):336-45. doi: 10.1002/hep.24052. Review.

PMID:
21254181
[PubMed - indexed for MEDLINE]
11.

Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review.

Donato MF, Fabrizi F, Fogazzi GB, Cresseri D, Passerini P, Martin P, Messa P.

Int J Artif Organs. 2013 Jan;36(1):63-8. doi: 10.5301/ijao.5000166. Review.

PMID:
23280083
[PubMed - indexed for MEDLINE]
12.

Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.

Bruno R, Sacchi P, Cima S, Maiocchi L, Novati S, Filice G, Fagiuoli S.

J Viral Hepat. 2012 Jan;19 Suppl 1:33-6. doi: 10.1111/j.1365-2893.2011.01519.x. Review.

PMID:
22233411
[PubMed - indexed for MEDLINE]
13.

Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C.

Rumi M, Aghemo A, Prati GM.

J Viral Hepat. 2012 Jan;19 Suppl 1:37-41. doi: 10.1111/j.1365-2893.2011.01525.x. Review.

PMID:
22233412
[PubMed - indexed for MEDLINE]
14.

An overview of emerging therapies for the treatment of chronic hepatitis C.

Ilyas JA, Vierling JM.

Clin Liver Dis. 2011 Aug;15(3):515-36. doi: 10.1016/j.cld.2011.05.002. Review.

PMID:
21867934
[PubMed - indexed for MEDLINE]
15.

Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature.

López V, Molina I, Monteagudo C, Jordá E.

Int J Dermatol. 2011 Mar;50(3):287-91. doi: 10.1111/j.1365-4632.2010.04728.x. Review.

PMID:
21342161
[PubMed - indexed for MEDLINE]
16.

1990-2010: two decades of interferon-based therapy.

Buti M, Esteban R.

Clin Liver Dis. 2011 Aug;15(3):473-82. doi: 10.1016/j.cld.2011.05.007. Epub 2011 Jun 14. Review.

PMID:
21867931
[PubMed - indexed for MEDLINE]
17.

Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.

Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, Atzeni F, Saccardo F, Quartuccio L, Bruno S, Bruno R, Campanini M, Candela M, Castelnovo L, Gabrielli A, Gaeta GB, Marson P, Mascia MT, Mazzaro C, Mazzotta F, Meroni P, Montecucco C, Ossi E, Piccinino F, Prati D, Puoti M, Riboldi P, Riva A, Roccatello D, Sagnelli E, Scaini P, Scarpato S, Sinico R, Taliani G, Tavoni A, Bonacci E, Renoldi P, Filippini D, Sarzi-Puttini P, Ferri C, Monti G, Galli M.

Autoimmun Rev. 2011 Jun;10(8):444-54. doi: 10.1016/j.autrev.2011.01.008. Epub 2011 Feb 15. Review.

PMID:
21303705
[PubMed - indexed for MEDLINE]
18.

[Anti-interferon antibody in chronic hepatitis C].

Arai K, Shindo M, Okuno T.

Nihon Rinsho. 1994 Jul;52(7):1929-34. Review. Japanese.

PMID:
7521441
[PubMed - indexed for MEDLINE]
19.

Diagnosis and treatment of chronic hepatitis C infection.

Patel K, Muir AJ, McHutchison JG.

BMJ. 2006 Apr 29;332(7548):1013-7. Review. No abstract available.

PMID:
16644828
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects.

Calvaruso V, Mazza M, Almasio PL.

Expert Opin Drug Saf. 2011 May;10(3):429-35. doi: 10.1517/14740338.2011.559161. Epub 2011 Feb 16. Review.

PMID:
21323500
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk